GLPwatch
Adlyxin for Parkinson's disease
lixisenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCAdlyxin (lixisenatide) is not FDA-approved for Parkinson's disease, and any use for this condition is off-label or investigational. Research suggests lixisenatide may enhance neurogenesis and has shown neuroprotective effects in animal models of Parkinson's disease, with ongoing trials exploring its efficacy and safety in early Parkinson's patients.
AI summary of the sources below.
| Drug | Adlyxin (lixisenatide) |
|---|---|
| Condition | Parkinson's disease |
| Approval status | Investigational / off-label |
| Research papers | 5 |
Adlyxin is not FDA-approved for parkinson's disease; the research below reflects investigational or off-label study only.
Research on lixisenatide for parkinson's disease (5)
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- Trial of Lixisenatide in Early Parkinson's Disease.
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
- Lixisenatide in early parkinson's disease: efficacy, safety, and future directions: a correspondence.
- Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?